FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma
NCT02023593
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Advanced Esophageal Carcinoma
Interventions
DRUG:
FOLFIRI
Sponsor
Yuhong Li